The study, published in NPJ Vaccines, tested the vaccine on mice and monkeys with positive results. The vaccine lowers LDL cholesterol almost as effectively as PCSK9 inhibitors, according to a Dec. 14 system news release. It has been tested over the past decade on monkeys and mice with “promising results,” the release said
“The vaccine is based on a non-infectious virus particle,” lead author Bryce Chackerian, PhD, a professor in the molecular genetics and microbiology department at the university, said in the release. “It is just the shell of a virus, and it turns out that we can use that shell of a virus to develop vaccines against all sorts of different things.”
The vaccine could be cheaper than $100 per dose.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
